(Q47321113)

14 January 2018

title

The long-term effects of rosiglitazone on serum lipid concentrations and body weight (English)

1 reference

14 January 2018

1 reference

Wan Sub Shim

1

1 reference

14 January 2018

Mi Young Do

2

1 reference

14 January 2018

Soo Kyung Kim

3

1 reference

14 January 2018

Hae Jin Kim

4

1 reference

14 January 2018

Kyu Yeon Hur

5

1 reference

14 January 2018

Eun Seok Kang

6

1 reference

14 January 2018

Chul Woo Ahn

7

1 reference

14 January 2018

Sung Kil Lim

8

1 reference

14 January 2018

Hyun Chul Lee

9

1 reference

14 January 2018

Bong Soo Cha

10

1 reference

14 January 2018

publication date

1 October 2006

1 reference

14 January 2018

published in

Clinical Endocrinology

1 reference

14 January 2018

volume

65

1 reference

14 January 2018

issue

4

1 reference

14 January 2018

page(s)

453-459

1 reference

14 January 2018

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Insulin resistance and its treatment by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

Effect of thiazolidinediones on body weight in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02614.X

10.1111/J.1365-2265.2006.02614.X

21 January 2018

Identifiers

DOI

1 reference

14 January 2018

PubMed ID

16984237

1 reference

14 January 2018